title: Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.
abstract: For macrolides, clinical activity but also the development of bacterial resistance has been attributed to prolonged therapeutic and subtherapeutic concentrations. Although erythromycin is a long-established antimicrobial, concomitant determination of the pharmacokinetics of erythromycin and its metabolites in different compartments is limited. To better characterize the pharmacokinetics of erythromycin and its anhydrometabolite (anhydroerythromycin [AHE]) in different compartments during and after the end of treatment with 500 mg of erythromycin four times daily, concentration-time profiles were determined in plasma, interstitial space of muscle and subcutaneous adipose tissue, and white blood cells (WBCs) at days 1 and 3 of treatment and 2 and 7 days after end of therapy. In WBCs, concentrations of erythromycin exceeded those in plasma approximately 40-fold, while free concentrations in plasma and tissue were comparable. The observed delay of peak concentrations in tissue might be caused by fast initial cellular uptake. Two days after the end of treatment, subinhibitory concentrations were observed in plasma and interstitial space of both soft tissues, while 7 days after the end of treatment, erythromycin was not detectable in any compartment. This relatively short period of subinhibitory concentrations may be advantageous compared to other macrolides. The ratio of erythromycin over AHE on day 1 was highest in plasma (2.81 ± 3.45) and lowest in WBCs (0.27 ± 0.22). While the ratio remained constant between single dose and steady state, after the end of treatment the concentration of AHE declined more slowly than that of the parent compound, indicating the importance of the metabolite for the prolonged drug interaction of erythromycin.
authors.affiliation: Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Krasniqi
authors.forename: P
authors.initials: P
authors.lastname: Matzneller
authors.forename: M
authors.initials: M
authors.lastname: Kinzig
authors.forename: F
authors.initials: F
authors.lastname: Sörgel
authors.forename: S
authors.initials: S
authors.lastname: Hüttner
authors.forename: E
authors.initials: E
authors.lastname: Lackner
authors.forename: M
authors.initials: M
authors.lastname: Müller
authors.forename: M
authors.initials: M
authors.lastname: Zeitlinger
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D001424:Bacterial Infections / Q000188:drug therapy; D004347:Drug Interactions; D004917:Erythromycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D007962:Leukocytes / Q000166:cytology / Q000378:metabolism*; D008297:Male; D009132:Muscles / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D000900:Anti-Bacterial Agents; C522888:anhydroerythromycin A; D004917:Erythromycin
references.citation: J Pharm Sci. 1976 Apr;65(4):497-502
references.pmid: 5588
references.citation: Biochem Pharmacol. 1991 Nov 6;42(11):2085-90
references.pmid: 1958226
references.citation: Am J Vet Res. 1999 Apr;60(4):414-9
references.pmid: 10211682
references.citation: Antimicrob Agents Chemother. 2005 Jun;49(6):2372-7
references.pmid: 15917536
references.citation: J Antimicrob Chemother. 1989 Nov;24(5):719-29
references.pmid: 2599996
references.citation: Antimicrob Agents Chemother. 1985 Mar;27(3):314-9
references.pmid: 3994346
references.citation: J Antimicrob Chemother. 1993 May;31 Suppl D:1-16
references.pmid: 8335512
references.citation: Antimicrob Agents Chemother. 1999 Aug;43(8):2056-8
references.pmid: 10428936
references.citation: Antimicrob Agents Chemother. 1981 Feb;19(2):335-6
references.pmid: 6812492
references.citation: Drug Metab Dispos. 2011 Oct;39(10):1808-14
references.pmid: 21730030
references.citation: J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82
references.pmid: 2154441
references.citation: J Clin Microbiol. 2002 Aug;40(8):2959-63
references.pmid: 12149359
references.citation: Antimicrob Agents Chemother. 1985 Nov;28(5):630-3
references.pmid: 4091529
references.citation: J Antimicrob Chemother. 1986 Jul;18(1):73-82
references.pmid: 3759725
references.citation: J Antimicrob Chemother. 2010 Jul;65(7):1433-40
references.pmid: 20472695
references.citation: Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S233-7
references.pmid: 11524724
references.citation: Infection. 1995;23 Suppl 1:S10-4
references.pmid: 7782109
references.citation: J Infect Dis. 1984 May;149(5):714-8
references.pmid: 6726002
references.citation: Int J Antimicrob Agents. 2001;18 Suppl 1:S17-23
references.pmid: 11574190
references.citation: Clin Ther. 1996 Jan-Feb;18(1):56-72; discussion 55
references.pmid: 8851453
references.citation: Lancet. 2007 Feb 10;369(9560):482-90
references.pmid: 17292768
references.citation: Experientia. 1971 Apr 15;27(4):362
references.pmid: 5581079
references.citation: J Pharm Sci. 1972 Mar;61(3):425-8
references.pmid: 5062519
references.citation: Lancet. 2005 Feb 12-18;365(9459):579-87
references.pmid: 15708101
references.citation: Clin Pharmacol Ther. 1995 Apr;57(4):371-80
references.pmid: 7712664
references.citation: Emerg Infect Dis. 2003 Apr;9(4):432-7
references.pmid: 12702222
references.citation: Pharm Res. 2007 May;24(5):1014-25
references.pmid: 17458685
references.citation: J Antimicrob Chemother. 2007 Aug;60 Suppl 1:i43-47
references.pmid: 17656380
references.citation: Clin Pharmacokinet. 2009;48(1):23-38
references.pmid: 19071882
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3185-9
references.pmid: 17606673
references.citation: J Immunol Methods. 1990 May 8;129(1):143-5
references.pmid: 2110946
references.citation: N Engl J Med. 1997 Aug 14;337(7):441-6
references.pmid: 9250845
references.citation: J Antimicrob Chemother. 2000 Aug;46(2):255-62
references.pmid: 10933649
references.citation: J Antimicrob Chemother. 1988 Jun;21 Suppl D:101-6
references.pmid: 3391871
references.citation: J Chemother. 1999 Feb;11 Suppl 1:35-43
references.pmid: 10207772
references.citation: Expert Rev Anti Infect Ther. 2006 Jun;4(3):479-90
references.pmid: 16771624
references.citation: Chest. 2010 Nov;138(5):1202-12
references.pmid: 21051396
references.citation: Antimicrob Agents Chemother. 2003 Nov;47(11):3548-53
references.pmid: 14576116
references.citation: AAPS J. 2005 Oct 22;7(3):E600-8
references.pmid: 16353939
references.citation: Antimicrob Agents Chemother. 2006 Nov;50(11):3646-50
references.pmid: 16940064
references.citation: Int J Antimicrob Agents. 2002 Apr;19(4):355-8
references.pmid: 11978507
references.citation: Int J Antimicrob Agents. 2002 Apr;19(4):333-9
references.pmid: 11978504
references.citation: Clin Infect Dis. 2007 Apr 15;44(8):1091-5
references.pmid: 17366456